ProMIS Neurosciences is trading 6.6% up at $16.20 today, extending a multi-day rally following positive clinical updates for its Alzheimer’s treatment candidate, PMN310.
- The company reported the first human evidence of amyloid-beta oligomer target engagement by PMN310, alongside a clean safety profile.
- Encouraging progress in the PRECISE-AD Phase 1b study allows for dose escalation, supporting continued investor optimism and upside momentum.